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Is Transcatheter Aortic Valve Replacement Better Than Surgical
Aortic Valve Replacement in Patients With Chronic Obstructive
Pulmonary Disease? A Nationwide Inpatient Sample Analysis
Tomo Ando, MD; Oluwole Adegbala, MD, MPH; Emmanuel Akintoye, MD, MPH; Said Ashraf, MD; Mohit Pahuja, MD; Alexandros Briasoulis,
MD, PhD; Hisato Takagi, MD, PhD; Cindy L. Grines, MD; Luis Afonso, MD; Theodore Schreiber, MD
Background-—Chronic obstructive pulmonary disease (COPD) patients are at increased risk of respiratory related complications
after cardiac surgery. It is unclear whether transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement
(SAVR) results in favorable outcomes among COPD patients.
Methods and Results-—Patients were identiﬁed from the Nationwide Inpatient Sample database from 2011 to 2014. Patients with
age ≥60, COPD, and either went transarterial TAVR or SAVR were included in the analysis. A 1:1 propensity-matched cohort was
created to examine the outcomes. A matched pair of 1210 TAVR and 1208 SAVR patients was identiﬁed. Respiratory-related
complications such as tracheostomy (0.8% versus 5.8%; odds ratio [OR], 0.14; P<0.001), acute respiratory failure (16.4% versus
23.7%; OR, 0.63; P=0.002), reintubation (6.5% versus 10.0%; OR, 0.49; P<0.001), and pneumonia (4.5% versus 10.1%; OR, 0.41;
P<0.001) were signiﬁcantly less frequent with TAVR versus SAVR. Use of noninvasive mechanical ventilation was similar between
TAVR and SAVR (4.1% versus 4.8%; OR, 0.84; P=0.41). Non-respiratory-related complications, such as in-hospital mortality (3.3%
versus 4.2%; OR, 0.64; P=0.035), bleeding requiring transfusion (9.9% versus 21.7%; OR, 0.38; P<0.001), acute kidney injury (17.7%
versus 25.3%; OR, 0.63; P<0.001), and acute myocardial infarction (2.4% versus 8.4%; OR, 0.19; P<0.001), were signiﬁcantly less
frequent with TAVR than SAVR. Cost ($56 099 versus $63 146; P<0.001) and hospital stay (mean, 7.7 versus 13.0 days; P<0.001)
were also more favorable with TAVR than SAVR.
Conclusions-—TAVR portended signiﬁcantly fewer respiratory-related complications compared with SAVR in COPD patients. TAVR
may be a preferable mode of aortic valve replacement in COPD patients. ( J Am Heart Assoc. 2018;7:e008408. DOI: 10.1161/
JAHA.117.008408.)
Key Words: chronic obstructive pulmonary disease • surgical aortic valve replacement • transcatheter aortic valve
replacement • transcutaneous aortic valve implantation
C hronic obstructive pulmonary disease (COPD) is acommon comorbidity that portends signiﬁcant impact
on decision making among candidates undergoing aortic valve
replacement for severe, symptomatic aortic stenosis.1 Surgi-
cal aortic valve replacement (SAVR), compared with tran-
scatheter aortic valve replacement (TAVR), may require longer
duration of mechanical ventilation, thus adversely affecting
patients’ outcomes especially among those with COPD.
Therefore, TAVR may confer added advantage over SAVR in
COPD patients requiring aortic valve replacement. The
negative impact of COPD has been evaluated in both TAVR
and SAVR for those with and without COPD.2–5 However,
comparative outcome data between TAVR versus SAVR have
not been extensively investigated.
TAVR could potentially offer clinical beneﬁt especially in
COPD patients given that it could be performed under local or
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moderate sedation without mechanical ventilation. In addi-
tion, cost and length of stay may favor TAVR compared with
SAVR.
The main purpose of this analysis was to better deﬁne the
optimal mode of aortic valve replacement in COPD patients
using the Nationwide Inpatient Sample (NIS) database.
Methods
The data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure because the
NIS database is publicly available data. The requirement for
institutional review board approval was waived for the same
reason.
Data Source
The NIS was used to derive patient-relevant information
between January 2011 and December 2014. The NIS is the
largest publicly available all-payer administrative claims-based
database and contains encounter-level information of hospital
stays compiled in a uniform format with privacy protection of
individual patients. Each year, over 7 million hospital stays
are sampled nationwide, which, when weighted, estimates
more than 35 million hospitalizations annually. These data are
stratiﬁed to represent 20% of US inpatient hospitalizations
across different hospital and geographical regions (random
sample). National estimates of the entire US hospitalized
population were calculated using the Agency for Healthcare
Research and Quality sampling and weighting method
(https://www.hcup-us.ahrq.gov/).
Study Population
COPD patients aged ≥60 years with aortic stenosis who
underwent SAVR (35.21, 35.22) or transarterial TAVR (35.05)
during the study period were identiﬁed using International
Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation
(ICD-9-CM) codes. We excluded patients with a diagnosis of
aortic insufﬁciency (395.1, 746.4, and 396.3) without a
diagnosis of aortic stenosis (395.0, 395.2, 396.0, 396.2,
424.1, and 746.3) and those who had concomitant coronary
artery bypass graft (36.1), mitral valve surgery (35.23, 35.24),
pulmonary valve surgery (35.25, 35.26), tricuspid valve
surgery (35.27, 35.28), and atrium or ventricular septum
defect closure (35.5, 35.6, and 35.7) because combined
surgery may affect the outcomes.
Covariates
Data on patient- and hospital-level characteristics were
provided for each patient in the NIS. However, identity
variables were not included to preserve both patient and
hospital privacies. Other potentially confounding exposures
were included presence or absence of the Elixhauser
comorbidities.
We examined both respiratory- and non-respiratory-related
outcomes. Respiratory-related outcomes included tra-
cheostomy, noninvasive mechanical ventilation, reintubation,
acute respiratory failure, and pneumonia. Non-respiratory-
related outcomes were inpatient mortality, bleeding requiring
transfusion acute kidney Injury, venous thromboembolism,
stroke, postoperative sepsis, need for permanent pacemaker,
and acute myocardial infarction. All of the clinical outcomes
were estimated in-hospital because only in-hospital outcomes
are available in the NIS database. Assessment of healthcare
resource was performed by comparing nonroutine home
discharge rate, cost, and length of stay. Hospital cost data
were queried from the hospital accounting reports from the
Centers for Medicare and Medicaid Services.
To account for demographic factors, we included race
(whites, non-Hispanic blacks, Hispanics, and others), sex
(female and male), health insurance type (Medicare, Medicaid,
private, self-pay, and others), and income level based on the
ZIP code (lowest quartile, second quartile, third quartile, and
highest quartile). We also included for hospital-level factors:
region (Northeast, Midwest, South, and West), teaching status
(rural, urban nonteaching, and urban teaching), and hospital
size (small, medium, and large sizes).
Clinical Perspective
What Is New?
• Patients with chronic obstructive pulmonary disease may
beneﬁt signiﬁcantly by experiencing lower in-hospital mor-
tality as well as fewer respiratory-related outcomes, includ-
ing tracheostomy, re-intubation, pneumonia, and acute
respiratory failure.
• Cost and length of stay were signiﬁcantly lower and shorter
in the transcatheter aortic valve replacement group in
chronic obstructive pulmonary disease patients compared
with surgical aortic valve replacement.
What Are the Clinical Implications?
• Symptomatic, severe aortic stenosis patients with chronic
obstructive pulmonary obstructive disease should strongly
be considered for transcatheter rather than surgical aortic
valve replacement given the signiﬁcantly lower in-hospital
mortality rates and respiratory-related complications.
• Further study is warranted to further investigate whether
different stage of chronic obstructive pulmonary disease
similarly beneﬁt from transcatheter compared with surgical
aortic valve replacement strategy.
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Outcome and exposures were all identiﬁed with ICD-9-CM
codes (Data S1, Table S1). To estimate the cost of hospital-
ization, the NIS data were merged with cost-to-charge ratios
available from the Healthcare Cost and Utilization Project. We
estimated the cost of each inpatient stay by multiplying the
total hospital charge with cost-to-charge ratios.
Propensity Score
We performed a comparative analysis between outcomes of
TAVR and SAVR in COPD patients. To account for potential
confounding factors and reduce the effect of selection bias, a
propensity-score–matching model was developed to derive 2
matched groups for comparative outcomes analysis. Propen-
sity score was calculated using multivariable logistic regression
models derived from hospital level, clinical, and demographic
covariates, including the Elixhauser comorbidities (Table S2).
For calculation of the propensity score, the dependent variable
was the TAVR versus SAVR procedure use. We performed
matching on the propensity score implementing a greedy
algorithm (gmatch macro) to construct a balanced match of
TAVR cases to SAVR cases in a 1:1 ratio using a caliper of 0.1.
Finally, 1210 TAVR cases were selected for the propensity-
matched population. We assessed the success of the match by
performing McNemar’s test for categorical variables and paired
t test for normally distributed continuous variables.
Statistical Analysis
National estimates were calculated using the hospital dis-
charge/trendweight provided for theNIS. Descriptive statistics
are presented as percentages for categorical variables and as
means with SDs for continuous variables. Baseline character-
istics were compared using a chi-square test for categorical
variables and an independent-samples t test for continuous
variables. Univariate logistic regression was performed to
estimate odds ratios (ORs) with 95% conﬁdence intervals to
compare tracheostomy, pneumonia, noninvasive mechanical
ventilation, inpatient mortality, bleeding requiring transfusion,
reintubation, acute respiratory failure, acute kidney injury,
venous thromboembolism, postoperative sepsis, acutemyocar-
dial infarction, new pacemaker implantation, stroke, and
nonroutine home discharge. Discrete numerical variables with
an overdispersed count distributions—length of stay and
continuous variables with a right-skewed spread—cost of
hospitalization were modeled using a generalized linear
regression (GENMOD) with a negative binomial function and
gamma function, respectively. The GENMOD procedures were
performed using the CLASS, WEIGHT, and REPEATED state-
ments to account for the clustered sampling and in-hospital
correlations. Matched categorical variables were presented as
percentages and compared using McNemar’s test. Matched
continuous variables were presented as means with SDs and
compared using a paired-samples t test with the STRATA,
CLUSTER, and WEIGHT and the SURVEYMEANS procedure to
account for the complex clustered sampling methodology as
recommended by the Healthcare Cost and Utilization Project.
All variables were 100% present besides race (6.56%), health
insurance type (0.17%), and average household income by ZIP
code (2.13%). Because race, health insurance type and health
insurance type were all missing at random, all missing
observations for the 3 variables were excluded, and a complete
case analysis was performed.
All the statistical tests were 2-tailed, P<0.05 was chosen a
priori, and the P values, ORs, and 95% conﬁdence intervals
were reported. All the statistical models were performed in
SAS software (version 9.4; SAS Institute Inc, Cary, NC).
Results
Patient Characteristics
A total of unweighted 7548 (1595 TAVR and 5953 SAVR)
patients were identiﬁed. In unmatched cohorts, as expected,
TAVR patients were signiﬁcantly older (80.67.1 versus
73.67.3 years; P<0.001), more often female (40.8% versus
34.1%; P<0.001), and had higher proportion of Elixhauser
score ≥4 (71.6% versus 66.4%; P<0.001). After 1:1 propen-
sity-score matching, a matched pair of 1210 TAVR and 1208
SAVR patients was identiﬁed. Patient characteristics were
well matched between the 2 groups (Tables 1 and 2).
Clinical Outcomes in Propensity-Matched Cohorts
Tracheostomy (0.8% versus 5.8%; OR, 0.14; P<0.001), acute
respiratory failure (16.4% versus 23.7%; OR, 0.63; P=0.002),
reintubation (6.5% versus 10.0%; OR, 0.49; P<0.001), and
pneumonia (4.5% versus 10.1%; OR, 0.41; P<0.001) were
signiﬁcantly lower in TAVR than SAVR. Use of noninvasive
mechanical ventilation was similar in TAVR and SAVR groups
(4.1% versus 4.8%; OR, 0.84; P=0.41).
Regarding non-respiratory-related clinical events, in-hospi-
tal mortality (3.3% versus 4.2%; OR, 0.64; P=0.035), bleeding
requiring transfusion (9.9% versus 21.7%; OR, 0.38; P<0.001),
acute kidney injury (17.7% versus 25.3%; OR, 0.63; P<0.001),
postoperative sepsis (0.83% versus 4.3%; OR, 0.19; P<0.001),
and acute myocardial infarction (2.4% versus 8.4%; OR, 0.19;
P<0.001) were signiﬁcantly less frequent in TAVR than SAVR.
New pacemaker placement was more frequently observed in
TAVR (9.8% versus 6.2%; OR, 1.6; P=0.001). Other secondary
end points not related to the respiratory system, including
venous thromboembolism (1.3% versus 1.3%; OR, 1.01;
P=0.98), and stroke (1.2% versus 1.2%; OR, 0.99; P=0.97)
were comparable between groups (Figures 1 and 2).
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Table 1. Baseline Characteristics of COPD Participants Undergoing TAVR or SAVR Between 2011 and 2014 in the United States—
Unmatched
Total TAVR SAVR P Value
No. of observation, unweighted 7548 1595 5953
No. of observation, weighted 37 102 7945 29 157
Age, y, mean (SD) 75.09 (7.81) 80.63 (7.07) 73.61 (7.32) <0.0001
Female, % 35.59 40.84 34.16 <0.0001
Race/ethnicity, % 0.006
White 88.35 89.30 88.10
Black 3.90 3.20 4.09
Hispanic 3.94 2.78 4.25
Asia 0.81 0.88 0.79
Others 3.00 3.84 2.78
COPD with oxygen dependence, % 7.13 16.86 4.47 <0.0001
Peripheral vascular disease, % 27.90 33.41 26.39 <0.0001
Hypertension, % 77.30 78.93 76.86 0.081
Rheumatological disorder, % 4.15 6.03 3.64 <0.0001
Hypothyroidism, % 15.26 19.93 13.98 <0.0001
Diabetes mellitus, % 35.33 37.06 34.86 0.104
Obesity, % 21.41 18.37 21.73 0.004
Chronic blood loss, % 1.38 1.07 1.46 0.231
Anemia deficiency, % 22.98 26.64 21.98 <0.0001
Congestive heart failure, % 4.47 13.03 2.14 <0.0001
Depression, % 8.75 8.46 8.83 0.647
Renal failure, % 24.79 36.45 21.61 <0.0001
Liver disease, % 2.12 2.18 2.11 0.849
Lymphoma, % 0.81 1.25 0.68 0.023
Alcohol abuse, % 3.29 1.56 3.76 <0.0001
Metastasis, % 0.23 0.31 0.20 0.397
Neurological disorders, % 5.64 6.03 5.55 0.457
Pulmonary circulatory disease, % 1.68 4.59 0.89 <0.0001
Electrolyte, % 36.01 25.60 38.85 <0.0001
Smoking, % 49.69 38.85 52.64 <0.0001
Elixhauser score, % 0.0004
0 to 1 2.25 1.88 2.35
2 to 3 30.28 26.53 31.30
≥4 67.47 71.59 66.35
Hospital bed size, % <0.0001
Small 5.62 3.52 6.19
Medium 19.62 16.13 20.57
Large 74.77 80.35 73.24
Hospital location, % <0.0001
Rural 2.26 0.63 2.70
Continued
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Healthcare resources were utilized less in TAVR as repre-
sented by signiﬁcantly lower cost ($56 099 versus $63 146;
P<0.001), shorter hospital stay (mean, 7.7 versus 13.0 days;
P<0.001), and less nonroutine home discharge (64.4% versus
80.9%; OR, 0.43; P<0.001) compared with SAVR.
Discussion
In this study from a large national database, we compared in-
hospital clinical outcomes for both respiratory-related and
non-respiratory-related end points between TAVR and SAVR in
COPD patients. Most of the respiratory-related outcomes
signiﬁcantly favored TAVR compared with SAVR. In addition,
several non-respiratory-related outcomes were signiﬁcantly
lower in TAVR than SAVR.
Respiratory-Related Outcomes
There is a paucity of data regarding respiratory-speciﬁc out-
comes between TAVR versus SAVR in COPD patients. Dvir et al
reported comparative outcomes between TAVR and SAVR in
chronic lung disease, from a subgroup analysis of the PARTNER
(Placement of Aortic Transcatheter valve) trial. However, there
were no respiratory-speciﬁc outcomes reported, whichwould be
of great clinical interest in this speciﬁc population.6 Another
study by Auffret et al reported outcomes between TAVR versus
SAVR in lower-surgical-risk (Society of Thoracic Surgical
Predicted Risk of Mortality score <4% was 60.1%, 4–8% was
39.9%) patients with COPD. The primary end point (composite of
30-day respiratorymortality, prolonged ventilation, reintubation,
tracheostomy, acute respiratory distress syndrome, pneumonia,
or pneumothorax) was similar between the 2 groups (10.6%
versus 7.4%; P=0.32). In addition, most of these clinical events
were also similar between TAVR and SAVR.7
Our study differed in several aspects from the study by
Auffret et al. Most important, we included much larger cohorts
in both arms, which enabled more-detailed assessment of each
outcome by providing more-robust statistical power. Second-
ary, the surgical risk of our cohort was higher because the
indication for TAVR was mainly for high or prohibitive surgical
risk during 2011–2014. The high-surgical-risk cohort could
have experienced incremental beneﬁt from transarterial TAVR,
which is much less invasive compared with SAVR or transapical
TAVR. Last, we only included patients who underwent transar-
terial TAVR. The aforementioned studies included 20% to 30%
of transapical TAVR, which may lead to increased postrespi-
ratory complication.7 The vast majority (>95%) of TAVR was
performed under general anesthesia between 2011 and 2014
according to the Society of Thoracic Surgeons/American
College of Cardiology Transcatheter Valve Therapy Registry.
This suggests that both transarterial and transapical TAVR were
performed under general anesthesia.8 Therefore, the shorter
intubation period may be 1 of the reasons for favorable
respiratory-related outcomes in TAVR.
Table 1. Continued
Total TAVR SAVR P Value
Urban nonteaching 24.19 9.53 28.18
Urban teaching 73.55 89.84 69.11
Expected primary payer, % <0.0001
Medicare 84.29 91.64 82.28
Medicaid 1.68 0.56 1.99
Private 11.74 5.85 13.35
Others 2.28 1.94 2.38
Median household income in quartile, % <0.0001
1st 25.98 23.66 26.61
2nd 26.02 23.91 26.60
3rd 25.03 23.87 25.35
4th 22.96 28.56 21.44
Hospital region, % 0.003
Northeast 22.78 24.81 22.22
Midwest 20.31 18.36 20.85
South 38.70 40.66 38.17
West 18.21 16.17 18.76
COPD indicates chronic obstructive pulmonary disease; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.
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Table 2. Baseline Characteristics of COPD Participants Undergoing TAVR or SAVR Between 2011 and 2014 in the United States—
Matched 1: 1
Total TAVR SAVR P Value
No. of observation, unweighted 2418 1210 1208
No. of observation, weighted 11 910 6030 5879
Age, y, mean (SD) 79.39 (6.86) 79.52 (7.19) 79.25 (6.50) 0.335
Female, % 40.06 41.55 40.55 0.616
Race/Ethnicity, % 0.996
White 89.18 89.37 88.97
Black 3.19 3.15 3.23
Hispanic 3.15 3.15 3.14
Asia 1.00 0.99 1.01
Others 3.49 3.33 3.64
COPD with oxygen dependence, % 12.71 12.55 12.87 0.814
Coagulation disorder, % 22.80 24.04 21.52 0.140
Peripheral vascular disease, % 30.29 29.76 30.83 0.568
Hypertension, % 79.49 79.06 79.92 0.604
Rheumatological disorder, % 5.66 5.63 5.68 0.967
Hypothyroidism, % 18.25 19.17 17.31 0.238
Diabetes mellitus, % 36.72 37.11 36.33 0.692
Obesity, % 20.17 19.57 20.79 0.459
Chronic blood loss, % 0.986 0.912 1.06 0.709
Anemia deficiency, % 24.85 24.64 25.07 0.810
Congestive heart failure, % 6.35 6.71 5.97 0.452
Depression, % 8.79 8.67 8.92 0.831
Renal failure, % 33.64 32.37 33.93 0.769
Liver disease, % 2.44 2.38 2.50 0.844
Lymphoma, % 1.45 1.40 1.49 0.866
Alcohol abuse, % 1.54 1.64 1.43 0.670
Metastasis, % 0.46 0.41 0.50 0.758
Neurological disorder, % 5.97 5.63 6.31 0.485
Pulmonary circulatory disease, % 2.48 2.74 2.21 0.414
Electrolyte, % 28.11 28.43 27.77 0.718
Smoking, % 40.52 39.62 41.43 0.364
Elixhauser score, % 0.727
0 to 1 2.00 2.23 1.78
2 to 3 29.07 29.93 29.21
≥4 68.92 68.83 69.01
Hospital bed size, % 0.781
Small 3.98 4.22 3.73
Medium 17.87 17.59 18.16
Large 78.15 78.18 78.11
Hospital location, % 0.953
Rural 0.72 0.74 0.69
Continued
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Several explanations may account for the lower respira-
tory complication rates in transarterial TAVR compared with
SAVR. First, intubation duration could have been shorter in
transarterial TAVR and therefore resulted in fewer respiratory
complications. Although the NIS database does not capture
the duration of intubation postprocedure, the signiﬁcantly
Table 2. Continued
Total TAVR SAVR P Value
Urban nonteaching 11.68 11.85 11.51
Urban teaching 87.60 87.40 87.80
Expected primary payer, % 0.739
Medicare 91.66 91.48 91.86
Medicaid 0.91 0.74 1.09
Private 5.60 5.89 5.31
Others 1.82 1.90 1.75
Median household income in quartile, % 0.934
1st 23.78 23.41 24.16
2nd 23.79 23.83 23.76
3rd 24.51 25.02 24.00
4th 27.91 27.74 28.08
Hospital region, % 0.917
Northeast 26.05 25.77 26.34
Midwest 18.25 17.85 18.66
South 39.47 39.87 39.05
West 16.23 16.50 15.95
COPD indicates chronic obstructive pulmonary disease; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.
Figure 1. Incidence of perioperative complications. MI indicates myocardial infarction; NIMV, noninvasive
mechanical ventilation; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve
replacement; VTE, venous thromboembolism.
DOI: 10.1161/JAHA.117.008408 Journal of the American Heart Association 7
TAVR vs SAVR in COPD Ando et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
higher rate of tracheostomy and reintubation strongly
suggests a longer duration of ventilation in SAVR. Previous
studies have suggested that longer invasive ventilation time
has been associated with longer intensive unit and total
hospital stay, ventilator-associated pneumonia, and reintuba-
tion.9,10 Second, SAVR requires open sternotomy whereas
transarterial TAVR does not. Open cardiac surgery would
likely cause more pain and hence increased use of analgesia,
including opiates. These medications could suppress the
respiratory drive and may result in respiratory failure,
atelectasis, or aspiration pneumonia, therefore causing
adverse respiratory complications.
Our study ﬁlls in the gap from previous studies by
investigating (1) comparative outcome between transarterial
TAVR versus SAVR in predominantly high-risk patients,
(2) respiratory-speciﬁc outcomes, and (3) including larger
cohorts with solid statistical adjustments.
Non-Respiratory-Related Outcomes and
Healthcare Resource
Outcomes of non-respiratory-related outcomes generally
mirrored outcomes of TAVR versus SAVR in unselected
patients. Increased risk of bleeding, acute kidney injury, and
myocardial infarction may have had been further enhanced
by exclusion by of those who had transapical TAVR given that
this approach has been reported to be associated with
increased risk of these perioperative outcomes.11–13 Signif-
icantly lower in-hospital mortality is likely the result of lower
respiratory- as well as non-respiratory-related clinical events.
In-hospital mortality from the NIS for COPD patients was
numerically lower for TAVR when compared with 30-day
mortality of the PARTNER trial and the French registry (3.3%
versus 7.4% versus 10.8%, NIS, PARTNER, and French
registry, respectively).3,6 Mortality was also numerically lower
in the NIS for COPD patients compared with the PARTNER
trial in the SAVR cohort (4.2% versus 10.9%).6 These
comparisons, however, should be cautiously interpreted
given that the nature of the data differs signiﬁcantly
(randomized control study versus all-inclusive) and our study
only included transarterial TAVR.
The lower cost and nonroutine discharge and shorter
hospital stay in TAVR patients was similar to previous
studies in TAVR versus SAVR in unselected patients.14 Mean
cost of TAVR was $55 916, and it was signiﬁcantly lower
than that of SAVR. Medicare cost analysis showed that
TAVR hospital costs were higher compared with SAVR
(median, $50 200 versus $45 500; P<0.01), mainly at-
tributed to medical supply costs despite shorter hospital
and intensive care unit stay.15 However, a previous study
Figure 2. Forest plot for clinical end points between TAVR and SAVR in COPD patients. COPD indicates
chronic pulmonary obstructive disease; MI, myocardial infarction; NIMV, noninvasive mechanical ventilation;
OR, odds ratio; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; VTE,
venous thromboembolism.
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revealed that minimalist TAVR (use of local anesthesia, fully
percutaneous access/closure, monitor with transthoracic
echocardiography, and conscious sedation) was related with
signiﬁcantly lower cost ($45 485 versus $55 377) com-
pared with conventional TAVR (use of endotracheal intuba-
tion, general anesthesia, transesophageal echocardiography,
and pulmonary artery catheter hemodynamic monitoring),
which was the predominant strategy during this study
period.16 The minimalist TAVR approach could further
reduce respiratory-related complications and result in addi-
tional decrease in cost and length of stay in transarterial
TAVR in COPD patients. Analysis of NIS data after 2015,
which was not available when these analyses were
performed, is required to prove this hypothesis. In the
more-recent data from a large commercial TAVR database,
conscious sedation was used in 27.4% with the new-
generation, self-expanding valves.17 Use of new-generation
valves and minimalist TAVR technique may portend further
beneﬁt, especially in COPD patients.
Several limitations of our analysis should be acknowl-
edged. First, we were unable to further assess the outcomes
stratiﬁed to the severity of COPD. Those patients with only
mild COPD patients may not have had beneﬁt of transarterial
TAVR and thus could have resulted in similar outcomes
compared with TAVR. The subgroup analysis of TAVR versus
SAVR in unselected patients suggested that 1-year mortality
and stroke did not differ when COPD was stratiﬁed by
severity.14 However, because this was an exploratory analysis,
further study is necessarily to determine whether or not the
beneﬁt of transarterial TAVR is applicable to all severity of
COPD.
Second, this was a retrospective study using a large,
national representative database, and baseline characteristics
for TAVR and SAVR often differ owing to its different
indication. We applied propensity-matched analysis, but not
all confounders were reported and could have resulted in
biased results. However, we have included an extensive list
for variable adjustments and we consider that results are
robust. Third, the NIS does not capture the commonly used
EuroSCORE or the Society of Thoracic Surgeons Score, and
therefore we were unable to use these as propensity-matched
variables. Last, the NIS database is an administrative
database that may be susceptible to coding errors. However,
it has been applied to a wide variety of medical research and
is considered a highly reliable database when analyzed
appropriately.
In conclusion, TAVR portended signiﬁcantly fewer respira-
tory-related complications as well as certain non-respiratory-
related complications compared with SAVR in COPD patients.
In addition, TAVR resulted in less utilization of healthcare
resources. TAVR may be a preferable mode of aortic valve
replacement in COPD patients.
Disclosures
None.
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SUPPLEMENTAL MATERIAL 
Data S1. 
 
Patient safety indicators (PSI), based on ICD-9-CM codes and Medicare severity Diagnosis-
Related Groups, were established by the Agency for Healthcare Research and Quality to monitor 
preventable adverse events during hospitalization and each PSI has specific inclusion and 
exclusion criteria. PSI individual measure technical specifications, Version 5.0, March 2015 was 
used to identify & define preventable complications. 
Table S1. International Classification of Diseases, Clinical Modification (ICD-9-CM) codes used in the 
study. 
Procedures 
Endovascular TAVR 35.05 
SAVR 35.21, 35.22 
Others 
Aortic insufficiency 395.1, 746.4, and 396.3 
Aortic stenosis 395.0, 395.2, 396.0, 396.2, 424.1 and 746.3 
Mitral value surgery 35.23, 35.24 
Pulmonary value surgery 35.25, 35.26 
Tricuspid value surgery 35.27,35.28 
Atrium or ventricular septum defect closure 35.5,35.6, and 35.7 
CAGB 36.10 
Comorbidities 
Stroke/TIA 
V12.54, 430, 431, 432.0-432.9, 434.01, 434.11, 434.91, 435.0-
435.9 
Smoking V15.82, 305.1 
Chronic Obstructive Pulmonary Disease 491, 492, 494, 496 
Oxygen dependent V462 
In-Hospital Morbidity 
Procedural 
Post-op hemorrhage 998.11, 998.12, 285.1 
Bleeding requiring transfusion 99.0x 
Stroke 997.01, 997.02 
Cardiovascular 
Acute Myocardial Infarction 
410.01, 410.11, 410.21, 410.31, 410.41, 410.51, 
410.61,410.71,410.81,410.91, 411.1 
Pulmonary Embolism PSI 
Deep Vein Thrombosis PSI 
Pulmonary 
Pneumonia 480, 481, 482, 483, 484, 485, 486, 997.31, 997.32 
Noninvasive Ventilation 93.90 
Acute respiratory failure 518.81, 518.82, 518.84, 799.1, 786.09, 518.4, 518.51 
Re-intubation 96.03, 96.04, 96.05 
Tracheostomy 31.1, 31.21, 31.29 
Infectious 
Sepsis PSI 
Renal complication 
Acute kidney injury 584.5, 584.6, 584.7,584.8 584.9 
Table S2. Variables Used for Propensity Score Matching. 
Age 
Race 
Sex 
Hypertension 
Diabetes mellitus  
Congestive heart failure 
Peripheral vascular disease 
Pulmonary hypertension 
Hypercoagulable state 
Obesity 
Coronary artery disease 
Valvulopathy 
Chronic liver disease 
Electrolyte abnormalities 
Blood loss anemia 
Iron deficiency anemia 
Paralysis 
Neurologic disorders 
Chronic lung disease 
Depression 
Hypothyroidism 
Lymphoma 
Metastatic disease 
Solid tumors without metastasis 
Collagen vascular disease 
Weight loss 
Alcoholism 
Depression 
Drug abuse 
Smoking 
Psychosis 
Hospital teaching status 
Acquired immunodeficiency syndrome. 
Hospital region 
Expected Primary payer 
Hospital bed size 
Median Household income  
 
 
O 
Oxygen dependent 
 
 
